Introduction
Recently the Department of Health announced the introduction in England of universal voluntary HIV screening in early pregnancy to prevent vertical transmission from mother to child [1] . A number of issues, however, remain to be addressed. In particular, pharmaco-economic models that have been applied to HIV screening do not account for the possibility that women might become infected after they had initially been found HIV negative in early pregnancy [2, 3] . The importance of this was underlined by a recent French study in which ®ve HIV-infected infants ± 28% of the total number of infants vertically infected ± were born to mothers who were HIV-negative in early pregnancy and who acquired HIV later in pregnancy or after delivery [4] . The majority of infants become infected with HIV during labour or lactation [5] . If some women with undiagnosed HIV infection in late pregnancy could be found through a repeat offer of HIV testing a few weeks before delivery, appropriate and effective preventive interventions such as short-course antiretroviral prophylaxis, cesarean section and breastmilk substitution could be proposed to them.
An additional strategy to reduce HIV transmission during pregnancy or lactation is partner referral for HIV counselling and testing as part of a`parental' approach in early pregnancy. This strategy of partner testing could have the added bene®t of preventing some cases of HIV transmission to other adults, in particular to the pregnant woman. Both strategies of expanded HIV testing ± repeat and partner testing ± could prevent vertical transmission and expensive paediatric HIV-related care. Here, we report on the cost effectiveness of expanded HIV testing in London (England). Development of our pharmaco-economic model for antenatal HIV testing was possible because information on the costs of treating paediatric HIV recently became available [6] .
Data and methods
The cost effectiveness of expanded HIV testing was estimated using a decision model from the perspective of the National Health Service, building on a previously applied HIV-screening model [2] . It was estimated that universal voluntary antenatal screening in early pregnancy costs £3900 per life-year gained in London [2] . The original model was extended by including a repeat offer of testing a few weeks before or during delivery, or referring fathers or current partners for voluntary counselling and testing in early pregnancy as part of a`partner' approach. Both options were explored using universal versus selective scenarios. Selective scenarios involved those individuals at increased risk of HIV infection. This includes injecting drug users, people from areas of the world with high HIV incidence or prevalence, those who have recently contracted another sexually transmitted disease or whose partners have these characteristics [7] .
Costs and effects
Assumptions concerning costs remained largely unchanged from the original model [2] , particularly the costs of pre-test counselling and testing, post-test counselling, antiretroviral prophylaxis during delivery and for the newborn, vaginal delivery, cesarean section, breast-milk substitution, and lifetime costs of paediatric HIV-care (Table 1) . Lifetime costs of paediatric HIVcare of £178 300 were estimated using a progressionof-disease model that distinguishes indeterminate, asymptomatic, symptomatic non-AIDS and AIDS stages of HIV infection (varied in sensitivity analysis). A discount rate of 5% was used for future costs (varied in sensitivity analysis) [8] . Costs of short-course prophylaxis for a few weeks in late pregnancy is likely to be less than £100 [2] . Due to economies of scale, the introduction of a universal offer of HIV screening in early pregnancy can be expected to have resulted in reductions in counselling and testing costs (further a A discount rate of 5% was applied for costs in future years [8] referred to as testing costs) compared with the originally estimated £40 [9] . We therefore varied the testing costs down to £4, the marginal cost of the test itself.
One case of adult HIV infection was estimated to generate discounted lifetime costs of £101 600 (varied in sensitivity analysis). This assumes a progression-ofdisease time frame after HIV infection of 4 years undiagnosed HIV infection, 9 years diagnosed asymptomatic infection, 2 years symptomatic non-AIDS disease and 5 years following the diagnosis of AIDS [10] . Furthermore, the lifetime costs estimate re¯ects the midpoint of lower and higher medical costs for all stages of HIV infection, as recently estimated for England [11] .
Prevention of one vertical transmission was estimated to result in 14.4 discounted life-years gained for the child (70 years, discounted at the same rate as costs) [2] . If one case of HIV transmission to the mother is prevented through partner testing 6.4 discounted maternal life years are gained (30 non-discounted life years). Detection of adult HIV infection was assumed to result in a gain of 1 discounted year of life, due to earlier initiation of antiretroviral treatment (varied in sensitivity analysis). Estimated costs for 1 year of treatment and care for asymptomatic individuals, including antiretroviral triple treatment with a protease inhibitor, amounted to £12 300 [11] .
In the absence of preventive measures, probabilities for vertical transmission of 14% during lactation and 18% during pregnancy and vaginal delivery were assumed [2, 12, 13] , resulting in an overall vertical transmission probability of 29% assuming independent probabilities [2] . If HIV infection of the mother takes place during pregnancy a relatively short period remains for transmission during pregnancy. However, primary HIV infection is associated with a high viral load, which itself has been found to be correlated with an increased risk of vertical transmission [14, 15] . It is not unreasonable to assume that if HIV infection of the mother takes place during pregnancy, or even shortly after delivery, the probability of vertical transmission is relatively high. In the model the transmission rate of 29% was therefore maintained, which was reduced to 6% by combining short-course antiretroviral prophylaxis, cesarean section and breast-milk substitution [2, 14, 16] .
Scenarios
Four speci®c scenarios were considered: (i) universal repeat testing assumed that mothers who tested negative in the initial screening in early pregnancy would be offered repeat testing. Seropositive mothers, found through repeat testing, were assumed to take up all preventive interventions of short-course antiretroviral prophylaxis, cesarean section and breast-milk substitu-tion; (ii) universal partner testing assumed that fathers or current partners ± one per mother ± were offered testing together with the mother in early pregnancy; (iii) selective repeat testing assumed that mothers at increased risk who tested negative in the initial screening would be offered repeat testing and seropositive mothers, found through repeat testing, were assumed to take up all preventive interventions; (iv) selective partner testing assumed that fathers or current partners at increased risk were offered testing together with the mother in early pregnancy.
Pharmaco-economic analysis
Incremental cost effectiveness was expressed as net costs per life-year gained and was based on comparing universal voluntary HIV screening with and without repeat testing, with and without partner testing, and taken up either universally or selectively.
Threshold analyses were performed for testing costs [17] To correct for respective sizes of HIV epidemics in pregnancy, we assumed that the rate of HIV-infected infants in London for HIV-negative mothers in early pregnancy is also one-third of the French rate. So, up to seven infants may acquire HIV infection per 100 000 seronegative early pregnancies in London (note: the annual number of pregnancies in London is approximately 100 000).
We assumed that at least one vertical transmission per 100 000 seronegative early pregnancies could be averted in London by the strategies described above, and we present results for one to ®ve vertical transmissions averted per 100 000 seronegative early pregnancies. Obviously, universal approaches present a higher likelihood of averting vertical transmission(s) than selective approaches as the former also include those women targeted by the latter. However, in selective approaches only 15% of all pregnant women or partners are offered testing, implying a signi®cant reduction in investment costs [20] . Given the reduction in the vertical transmission rate of 23% due to preventive measures, we assumed that every vertical transmission averted by partner testing is accompanied by (1/0.23) 4.3 averted maternal infections.
Results are reported in the baseline analysis using the assumptions speci®ed above. As already indicated sensitivity analyses are presented which vary on the most relevant assumptions. This also includes the procedure of discounting the life-years gained. Some authors suggest at least discounting life-years gained at lower rates than the costs or not discounting them at all [21] .
Results
Baseline Universal repeat testing is cost saving if at least four vertical transmissions per 100 000 seronegative early pregnancies are averted in London at testing costs below £5 (Fig. 1, circles) . If a universal repeat offer of testing can avert at least two vertical transmissions per 100 000, net costs are below £10 000 per life-year gained if testing costs are £6 or less.
If one or more vertical transmissions per 100 000 seronegative early pregnancies is averted, universal partner testing is cost saving for testing costs below £6 and net costs per life-year gained are below £10 000 at testing costs of £10 or less (Fig. 1, squares In summary, testing costs in the range of £4±40 may translate into favourable incremental cost-effectiveness estimates of expanded antenatal HIV testing in London already at low numbers of vertical transmissions averted per 100 000 pregnant women who test negative in early pregnancy. Favourable cost effectiveness in scenarios of universal testing requires testing costs in the lower part of the range (, £10) and at least two vertical transmissions averted. Scenarios of selective testing already produce favourable cost-effectiveness outcomes at testing costs in the range of £10±40 and for one vertical transmission averted per 100 000 seronegative early pregnancies.
Sensitivity analysis
Recently it has been argued that the lower bound of the range for testing costs is currently most relevant for universal approaches [3] . Due to economies of scale, the introduction of universal voluntary antenatal screening has decreased pre-test counselling costs, thus lowering testing costs below the initial estimate of £40 [3] . Furthermore, a repeat test might not require intensive counselling again and in partner testing counselling can be provided for both partners together. Sensitivity analysis of universal expanded testing was therefore performed for testing costs of £4 and £10 ( Table 2 ).
Selective expanded testing will involve higher testing costs than for universal testing, as individual risk assessment has to be performed. Furthermore, pre-test counselling is more costly on a selective basis than if performed routinely. Sensitivity analysis of selective approaches was therefore directed at testing costs of £10 and £40 ( Table 3 ). As mentioned, the likelihood of averting vertical transmission is lower for selective than for universal approaches. Calculations underlying Table 3 were based on one vertical transmission averted per 100 000 seronegative early pregnancies (as compared to two in Table 2 ). 
Discussion
Implementation of expanded HIV testing could be a combination of both approaches investigated. A combined expanded testing could involve participation of some fathers or current partners in partner testing (universal or selective) and repeat testing of those mothers whose partners do not participate in testing. If, for example, we assume that the likelihood of a vertical transmission being averted by repeat offer equals that of being averted by partner testing, threshold testing costs for combined testing lie in between those for repeat and partner testing.
The likelihood of averting vertical transmission probably differs for different scenarios. As mentioned, universal approaches comprise those women also included by selective approaches, making the former more likely to avert vertical transmission than the latter. Furthermore, in the French study (that our analysis draws on) mothers of three out of the ®ve HIVinfected children had con®rmed late primary maternal infection during the breast-feeding period [4] , indicating that their infection possibly took place after delivery. Repeat testing would not have averted vertical transmission if maternal infection indeed took place after delivery. For these mothers, partner testing could have averted vertical transmission as all fathers of the HIV-infected children in the French study were found to be seropositive. Hence, the greatest likelihood of averting vertical transmission would be through a universal offer of partner testing.
Our incremental cost effectiveness relates net costs to vertical transmissions averted. As one consequence, partner testing approaches exhibit lower net costs per life-year gained than repeat testing approaches for similar numbers of vertical transmissions averted. This relates to the design of our model where partner testing does not only avert vertical transmission but also prevents transmission among partners. Neither possible reductions in HIV transmission associated with behavioural change once a parent learns about being infected with HIV, nor indirect costs of production losses were included in the model. Inclusion of these factors would strengthen the study's general conclusion that even at relatively low numbers of vertical transmissions averted, expanded antenatal HIV testing in London has a favourable cost effectiveness. Post-test counselling of seronegative women was not included as an alternative strategy in the current model. Continued counselling during pregnancy and the breast-feeding period may provide another option for averting vertical transmission [4] .
In sensitivity analysis, cost-effectiveness of expanded antenatal HIV testing ranges from cost-saving for partner testing to £6100 per discounted life-year gained for repeat testing. These estimates are comparable to or better than those for antenatal screening of hepatitis B for the whole of the UK at £2500 per undiscounted life-year gained [2, 23] . Increase in net costs would be several-fold for antenatal hepatitis B screening if expressed per discounted life-year gained. There is still disagreement among pharmaco-economists on whether or not to discount life-years gained [21, 22] .
Cost effectiveness of expanded HIV testing in London may be similar to or better than estimates in a number of US-studies in HIV prevention. Costs per life-year gained were estimated at US$10 000 (£6000) for combination antiretroviral therapy [24] and at US$47 200 (£28 200) for screening hospital patients [25] . Some US studies express results in net costs per HIV infection averted: US$67 000 (£40 000) for partner noti®cation of HIV-infected injecting drug users [26] and US$91 000 (£54 000) for a needle exchange programme in New Haven [27] . For comparison: at testing costs of £10 and one vertical transmission averted per 100 000 seronegative early pregnancies, our corresponding baseline estimates amount to, for example, £32 000 per (paediatric) HIV-infection averted for selective repeat testing and £81 000 per (paediatric or adult) HIV-infection averted for selective partner testing.
Conclusion
The availability of reliable cost information on HIV infected children in London [6] enabled the ®rst costeffectiveness analysis of expanded antenatal-HIV testing to be performed. Expanded antenatal HIV testing involves universal or selective repeat offer of HIV testing to pregnant women in late pregnancy, offer of testing to fathers or current partners together with the mother in early pregnancy or a combination of both. Given the potential of also averting HIV transmissions between partners, more favourable cost effectiveness is estimated for partner testing than for repeat testing.
If at least two vertical transmissions are averted per 100 000 pregnant women testing negative in early pregnancy, baseline estimates of net costs per life-year gained for expanded HIV testing in London are less than £10 000 for both universal and selective approaches, at testing costs of £4 and £10, respectively. Furthermore, over a broad range in sensitivity analysis net costs per life-year gained remain below £5000 for partner testing and below £40 000 for repeat testing. Even if universal partner testing would avert only one vertical transmission per 100 000 seronegative pregnancies in London at testing of £10, net costs per life-year gained are still below £10 000 per discounted life-year gained.
From the pharmaco-economic point of view taken by the authors, there is now suf®cient justi®cation to consider seriously the implementation of expanded antenatal HIV testing in London. Of course, prior to ®nal decision making, factors other than pharmacoeconomic ones should be considered including budgetary, ethical, social and psychologic aspects and potential uptake of expanded antenatal HIV testing.
